Christopher R Gordon
CIK 1432313 · last filed 2024-08-05
Christopher R Gordon is a corporate insider who has filed 34 SEC Form 4 insider transactions across 5 companies since 2011. Across all open-market trades the lifetime net is −$3.52B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.09B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HCA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
JOHN HANCOCK TOWER, 200 CLARENDON STREET
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 65,693,524 | $44.96 | $2.95B | $125.00M | 4 | 2024-06-07 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 60,632,356 | $18.07 | $1.10B | $103.42M | 3 | 2021-06-14 |
| ACHC | Director | 12,328 | $31.34 | $386.4K | -$366.54M | 8 | 2018-05-07 |
| Q | Director | 9,944,017 | $114.07 | $1.13B | -$901.86M | 10 | 2015-08-07 |
| HCA | Director | 30,003,156 | $465.26 | $13.96B | -$2.48B | 8 | 2013-11-05 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-05 | — | Disp (D) | −65,693,524 | $0 | |
| 2024-06-07 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | +10,461 | $0 | EDGAR |
| 2023-10-18 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Buy (P) | +5,480,052 | $125.00M | EDGAR |
| 2023-06-09 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | −429,345 | $0 | EDGAR |
| 2022-06-16 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-12 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Buy (P) | +332,293 | $3.42M | EDGAR |
| 2020-10-29 | Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Mixed | +59,961,943 | $100.00M | EDGAR |
| 2018-05-07 | ACHC | Grant (A) | +4,125 | $0 | EDGAR |
| 2017-08-24 | ACHC | Sell (S) | −998,438 | -$50.61M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.